| Trial ID: | L1762 |
| Source ID: | NCT02585804
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
|
| Acronym: |
TRANSLATE
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Focal Segmental Glomerulosclerosis
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: The change in Glomerular Filtration Rate (GFR) After an 8 week treatment with dapagliflozin, Glomerular Filtration Rate (GFR, based on plasma inulin clearance) will be measured at baseline and after 8 weeks of treatment., Before and after an 8 week treatment with dapagliflozin | Secondary: The change in Effective Renal Plasma Flow (ERPF) After an 8 week treatment with dapagliflozin, Effective Renal Plasma Flow (ERPF, based on paraaminohippurate plasma clearance) will be measured at baseline and after 8 weeks of treatment., Before and after an 8 week treatment with dapagliflozin|The change in Blood Pressure After an 8 week treatment with dapagliflozin, Before and after 8 weeks of treatment with dapagliflozin|The change in albuminuria after 8 weeks of treatment with dapagliflozin, Before and after 8 weeks of treatment with dapagliflozin|The change in urinary vasoactive mediators after 8 weeks of treatment with dapagliflozin, Before and after 8 weeks of treatment with dapagliflozin
|
| Sponsor/Collaborators: |
Sponsor: University Health Network, Toronto | Collaborators: AstraZeneca|University of Toronto|Toronto General Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2015-09
|
| Completion Date: |
2017-04-24
|
| Results First Posted: |
|
| Last Update Posted: |
2018-01-16
|
| Locations: |
Renal Physiology Laboratory, University Health Network, Toronto, Ontario, M5G 2N2, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02585804
|
